Patterns of minimal residual disease after high dose therapy in myeloma - A comparison of allografting and autografting.

被引：0
|
作者：
Haynes, AP
Carter, GI
Owen, R
Davis, F
Byrne, J
Bybee, A
Samsom, D
Morgan, GJ
Russell, NH
机构：
[1] CITY HOSP NOTTINGHAM,DEPT HAEMATOL,NOTTINGHAM,ENGLAND
[2] LEEDS GEN INFIRM,LEEDS,W YORKSHIRE,ENGLAND
[3] HAMMERSMITH HOSP,LONDON,ENGLAND
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：995 / 995
页数：1
相关论文
共 50 条
  • [1] Allografting with immunosuppressive conditioning of low-dose fludarabine-cyclophosphamide after autografting.
    Carella, AM
    Cavaliere, M
    Corsetti, MT
    Lerma, E
    BLOOD, 2000, 96 (11) : 553A - +
  • [2] High-dose (HDS) chemotherapy in multiple myeloma: Residual tumor cells are detectable in PBPC and BM cell harvests and after single or double autografting.
    Corradini, P
    Astolfi, M
    Ladetto, M
    Campana, S
    Comoglio, F
    Tarella, C
    Boccadoro, M
    Pileri, A
    BLOOD, 1995, 86 (10) : 810 - 810
  • [3] Reduced intensity conditioning regimen for allografting following autografting has strong anti-myeloma activity and delays disease progression compared to tandem autografting.
    Carella, A. M.
    Lerma, E.
    Nati, S.
    Congiu, A.
    Rossi, E.
    Spriano, M.
    Vimercati, R.
    BLOOD, 2006, 108 (11) : 20A - 20A
  • [4] Molecular monitoring of minimal residual disease after non-myeloablative allografting for multiple myeloma
    Bruno, B
    Ladetto, M
    Mordini, N
    Astolfi, M
    Rotta, M
    Cimolin, L
    Compagno, M
    Veneziano, L
    Aitoro, G
    Gallamini, A
    Storb, R
    Boccadoro, M
    BONE MARROW TRANSPLANTATION, 2003, 31 : S123 - S124
  • [5] Impact of previous high-dose therapy on outcome after allografting for multiple myeloma
    Kulkarni, S
    Powles, RL
    Treleaven, JG
    Singhal, S
    Saso, R
    Horton, C
    Killick, S
    Tait, D
    Ramiah, V
    Mehta, J
    BONE MARROW TRANSPLANTATION, 1999, 23 (07) : 675 - 680
  • [6] Impact of previous high-dose therapy on outcome after allografting for multiple myeloma
    S Kulkarni
    R L Powles
    J G Treleaven
    S Singhal
    R Saso
    C Horton
    S Killick
    D Tait
    V Ramiah
    J Mehta
    Bone Marrow Transplantation, 1999, 23 : 675 - 680
  • [7] Similar disease-free survival (DFS) after allografting and autografting for multiple myeloma (MM).
    Schlossman, RL
    Webb, I
    Alyea, EP
    Soiffer, RJ
    Fisher, D
    Vance, E
    Gribben, J
    Freedman, A
    Nadler, L
    Ritz, J
    Anderson, KC
    BLOOD, 1997, 90 (10) : 994 - 994
  • [8] Deletion 11q23 identifies B-CLL patients at high risk for molecular disease persistence after high dose therapy and autografting.
    Stilgenbauer, S
    von Neuhoff, N
    Bullinger, L
    Kröber, A
    Lichter, P
    Dreger, P
    Döhner, H
    BLOOD, 2000, 96 (11) : 715A - 715A
  • [9] Semi-nested PCR monitoring of minimal residual disease (MRD) in lymphoproliferative disorders following stem cell autografting.
    ColeSinclair, MF
    Messino, NM
    Kapuscinski, M
    DeFilippis, N
    Schwarer, AP
    BLOOD, 1997, 90 (10) : 3882 - 3882
  • [10] Low-dose preparative regimen and allogeneic stem cell transplantation in patients with multiple myeloma relapsing after autografting.
    Einsele, H
    Bamberg, M
    Schäfer, HJ
    Hebart, H
    Bader, P
    Budach, W
    Faul, C
    Brugger, W
    Kanz, L
    BLOOD, 1999, 94 (10) : 309B - 309B
12345